Food and Drug Administration vs European Medicines Agency: Review times and clinical evidence on novel drugs at the time of approval

DOI: 10.1111/bcp.14130
British Journal of Clinical Pharmacology, 2020, 86, 170-174.

#	Paper	IF	Citations
10	Food and Drug Administration vs European Medicines Agency: Review times and clinical evidence on novel drugs at the time of approval. *British Journal of Clinical Pharmacology*, **2020**, 86, 170-174	3.8	6
9	Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States. *Milbank Quarterly*, **2020**, 98, 1219-1256	3.9	10
8	Evolving Landscape of New Drug Approval in Japan and Lags from International Birth Dates: Retrospective Regulatory Analysis. *Clinical Pharmacology and Therapeutics*, **2021**, 109, 1265-1273	6.1	5
7	Transparency in European Medicines Agency and US Food and Drug Administration Decision Making: Is It Possible to Identify the Rationale for Divergences in Approved Indication From Public Assessment Reports?. *Clinical Therapeutics*, **2021**, 43, 888-905	3.5	
6	Current challenges in applying gene-driven therapies in clinical lung cancer practice. *World Journal of Clinical Oncology*, **2021**, 12, 656-663	2.5	0
5	Recent Clinical Trials on Natural Products and Traditional Chinese Medicine Combating the COVID-19. *Indian Journal of Microbiology*, **2020**, 61, 1-6	3.7	7
4	A detailed analysis of expedited regulatory review time of marketing authorization applications for new anticancer drugs in the US and EU.. *Clinical and Translational Science*, **2022**,	4.9	0
3	Transferability of real-world data across borders for regulatory and health technology assessment decision-making. 9,		0
2	Regional disparity in first-in-class anticancer drug development in the US, EU, and Japan. **2023**,		0
1	The role of drug regulatory authorities and health technology assessment agencies in shaping incentives for antibiotic R&D: a qualitative study. **2023**, 16,		0